SMMT Stock Summary and Trading Ideas (Summit Therapeutics | NASDAQ:SMMT)

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics trades on the NASDAQ stock market under the symbol SMMT.

As of December 13, 2024, SMMT stock price declined to $17.83 with 1,333,929 million shares trading.

SMMT has a beta of 3.16, meaning it tends to be more sensitive to market movements. SMMT has a correlation of 0.06 to the broad based SPY ETF.

SMMT has a market cap of $13.15 billion. This is considered a Large Cap stock.

In the last 3 years, SMMT traded as high as $33.89 and as low as $.66.

The top ETF exchange traded funds that SMMT belongs to (by Net Assets): VTI, VB, IWM, VXF, VBR.

SMMT has outperformed the market in the last year with a return of +662.0%, while the SPY ETF gained +29.9%. However, in the most recent history, SMMT shares have underperformed the stock market with its stock returning -44.2% in the last 3 month period and -3.4% for the last 2 week period, while SPY has returned +7.8% and +0.3%, respectively.

SMMT support price is $17.14 and resistance is $18.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SMMT shares will trade within this expected range on the day.